Venous thromboembolism Tranexamic acid allergy Tranexamic acid, Bilateral total knee arthroplasty, Total blood loss
Conditions
Interventions
Intravenous Tranexamic Acid (IV-TXA) Protocol
IV-TXA Administration: Patients will receive a total dose of 2 g of IV-TXA, administered in two divided doses:
First Dose: 1 g of TXA diluted in Normal S
Active Comparator Drug,Active Comparator Drug
Intravenous injection,Intraarticular injection
Sponsors
Chiangmai university
Eligibility
Sex/Gender
All
Age
55 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Age: Patients aged 55 years or older. 2.Diagnosis: Confirmed diagnosis of advanced knee osteoarthritis, classified as Kellgren-Lawrence (KL) Grade 3 or 4, with radiographic evidence. 3.Clinical History: Persistent symptoms despite conservative management (including pharmacological therapy) for a period exceeding 6 months. 4.Surgical Procedure: Patients undergoing simultaneous bilateral total knee arthroplasty (TKA).
Exclusion criteria
Exclusion criteria: 1.Medication Profile: Patients currently receiving anticoagulant or antiplatelet therapy. 2.Hematological Disorders: Patients with underlying hematological abnormalities, including: Coagulopathy (bleeding disorders), Thrombocytopenia (low platelet count), Anemia, specifically defined as a baseline Hematocrit (Hct) < 30%. 3.Drug Hypersensitivity: Patients with a known history of allergy or hypersensitivity to Tranexamic Acid (TXA).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcomes are Total blood loss, Blood transfusion rate, Length of stay, WOMAC score, Complication 3 months after intervention end Total Blood loss (Nadler, Gross formula) | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcomes are Blood transfusion rate, Length of stay, WOMAC score, Complication 3 months after intervention end Hemoglobin and Hematocrit | — |
Countries
Thailand
Contacts
Public ContactPhitsakrit Lertruangpanya
Chiangmai university
Outcome results
None listed